Jui Wan Loh1,2,3, Caitlin Guccione1, Frances Di Clemente2, Gregory Riedlinger1,2,4, Shridar Ganesan1,2,5, Hossein Khiabanian1,2,4. 1. Center for Systems and Computational Biology, Rutgers University, New Brunswick, NJ, USA. 2. Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, USA. 3. Graduate Program in Microbiology and Molecular Genetics, Rutgers University, Piscataway, NJ, USA. 4. Department of Pathology and Laboratory Medicine, Rutgers University, New Brunswick, NJ, USA. 5. Department of Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA.
Abstract
SUMMARY: Clinical sequencing aims to identify somatic mutations in cancer cells for accurate diagnosis and treatment. However, most widely used clinical assays lack patient-matched control DNA and additional analysis is needed to distinguish somatic and unfiltered germline variants. Such computational analyses require accurate assessment of tumor cell content in individual specimens. Histological estimates often do not corroborate with results from computational methods that are primarily designed for normal-tumor matched data and can be confounded by genomic heterogeneity and presence of sub-clonal mutations. Allele-frequency-based imputation of tumor (All-FIT) is an iterative weighted least square method to estimate specimen tumor purity based on the allele frequencies of variants detected in high-depth, targeted, clinical sequencing data. Using simulated and clinical data, we demonstrate All-FIT's accuracy and improved performance against leading computational approaches, highlighting the importance of interpreting purity estimates based on expected biology of tumors. AVAILABILITY AND IMPLEMENTATION: Freely available at http://software.khiabanian-lab.org. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
SUMMARY: Clinical sequencing aims to identify somatic mutations in cancer cells for accurate diagnosis and treatment. However, most widely used clinical assays lack patient-matched control DNA and additional analysis is needed to distinguish somatic and unfiltered germline variants. Such computational analyses require accurate assessment of tumor cell content in individual specimens. Histological estimates often do not corroborate with results from computational methods that are primarily designed for normal-tumor matched data and can be confounded by genomic heterogeneity and presence of sub-clonal mutations. Allele-frequency-based imputation of tumor (All-FIT) is an iterative weighted least square method to estimate specimen tumor purity based on the allele frequencies of variants detected in high-depth, targeted, clinical sequencing data. Using simulated and clinical data, we demonstrate All-FIT's accuracy and improved performance against leading computational approaches, highlighting the importance of interpreting purity estimates based on expected biology of tumors. AVAILABILITY AND IMPLEMENTATION: Freely available at http://software.khiabanian-lab.org. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
Authors: Peter Van Loo; Silje H Nordgard; Ole Christian Lingjærde; Hege G Russnes; Inga H Rye; Wei Sun; Victor J Weigman; Peter Marynen; Anders Zetterberg; Bjørn Naume; Charles M Perou; Anne-Lise Børresen-Dale; Vessela N Kristensen Journal: Proc Natl Acad Sci U S A Date: 2010-09-13 Impact factor: 11.205
Authors: Charlotte Pawlyn; Andrea Loehr; Cody Ashby; Ruslana Tytarenko; Shayu Deshpande; James Sun; Kyle Fedorchak; Tariq Mughal; Faith E Davies; Brian A Walker; Gareth J Morgan Journal: Leukemia Date: 2018-02-02 Impact factor: 11.528
Authors: Kim M Hirshfield; Denis Tolkunov; Hua Zhong; Siraj M Ali; Mark N Stein; Susan Murphy; Hetal Vig; Alexei Vazquez; John Glod; Rebecca A Moss; Vladimir Belyi; Chang S Chan; Suzie Chen; Lauri Goodell; David Foran; Roman Yelensky; Norma A Palma; James X Sun; Vincent A Miller; Philip J Stephens; Jeffrey S Ross; Howard Kaufman; Elizabeth Poplin; Janice Mehnert; Antoinette R Tan; Joseph R Bertino; Joseph Aisner; Robert S DiPaola; Lorna Rodriguez-Rodriguez; Shridar Ganesan Journal: Oncologist Date: 2016-08-26
Authors: Nahed Jalloul; Israel Gomy; Samantha Stokes; Alexander Gusev; Bruce E Johnson; Neal I Lindeman; Laura Macconaill; Shridar Ganesan; Judy E Garber; Hossein Khiabanian Journal: JCO Precis Oncol Date: 2021-11-17